Board Meeting26 May 2026, 06:12 pm
Morepen Labs Approves Addendum, FY26 Results, Dividend
AI Summary
Morepen Laboratories Ltd's board approved the second addendum to the Business Transfer Agreement with its subsidiary, Morepen Medipath Limited, revising the 'Appointed Date' to April 1, 2026. The board also approved the audited standalone and consolidated financial results for the year ended March 31, 2026, and recommended a final dividend of ₹0.20 per equity share. Additionally, M/s. Vijender Sharma & Co. was re-appointed as Cost Auditors for FY27.
Key Highlights
- Second addendum to Business Transfer Agreement with Morepen Medipath approved.
- Audited FY26 financial results approved with an unmodified opinion.
- Final dividend of ₹0.20 per share recommended for FY26.
- M/s. Vijender Sharma & Co. re-appointed as Cost Auditors for FY27.
Price Impact
More from MOREPENLAB